Summit Therapeutics Inc. (NASDAQ: SMMT) is -59.06% lower on its value in year-to-date trading and has touched a low of $0.66 and a high of $5.78 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The SMMT stock was last observed hovering at around $1.53 in the last trading session, with the day’s gains setting it 0.21% off its average median price target of $4.00 for the next 12 months. It is also 56.5% off the consensus price target high of $4.00 offered by 1 analysts, but current levels are 56.5% higher than the price target low of $4.00 for the same period.
Currently trading at $1.74, the stock is -7.18% and -43.77% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.09 million and changing 13.73% at the moment leaves the stock -2.90% off its SMA200. SMMT registered -37.63% loss for a year compared to 6-month gain of 30.83%.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
The stock witnessed a -25.16% loss in the last 1 month and extending the period to 3 months gives it a -55.61%, and is 26.09% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 14.72% over the week and 13.78% over the month.
Summit Therapeutics Inc. (SMMT) has around 105 employees, a market worth around $366.91M and $1.00M in sales. Distance from 52-week low is 163.64% and -69.90% from its 52-week high. The company has generated returns on investments over the last 12 months (-103.50%).
Summit Therapeutics Inc. (SMMT) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Summit Therapeutics Inc. (SMMT) is a “Hold”. 1 analysts offering their recommendations for the stock have an average rating of 1.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Summit Therapeutics Inc. is expected to release its quarterly report on 05/15/2023.The EPS is expected to shrink by -26.70% this year.
Summit Therapeutics Inc. (SMMT) Top Institutional Holders
The shares outstanding are 148.58M, and float is at 34.00M with Short Float at 17.71%.
Summit Therapeutics Inc. (SMMT) Insider Activity
The most recent transaction is an insider purchase by Zanganeh Mahkam,the company’sCo-Chief Executive Officer. SEC filings show that Zanganeh Mahkam bought 15,973,743 shares of the company’s common stock on Mar 08 at a price of $1.05 per share for a total of $16.77 million. Following the purchase, the insider now owns 23.4 million shares.
Summit Therapeutics Inc. disclosed in a document filed with the SEC on Mar 08 that Zanganeh Mahkam (Co-Chief Executive Officer) bought a total of 7,553,301 shares of the company’s common stock. The trade occurred on Mar 08 and was made at $1.05 per share for $7.93 million. Following the transaction, the insider now directly holds 9.88 million shares of the SMMT stock.
Still, SEC filings show that on Mar 07, Dhingra Ankur (Chief Financial Officer) acquired 196,362 shares at an average price of $1.05 for $0.21 million. The insider now directly holds 234,558 shares of Summit Therapeutics Inc. (SMMT).
